MOTS-c — clinical evidence
Assessed outcomes with certainty ratings, contributing trials and the reasoning for each rating.
§3Clinical evidence
§3.1Biological ageing and healthspan endpoints
Anchor outcome. Epigenetic age acceleration.
Effect as recorded. No randomised controlled human trial identified; —.[1,2]
Certainty. Very low certainty Observational associations between endogenous MOTS-c concentration and metabolic phenotype exist; these are associations, not intervention evidence.
Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.
Full evidence extract for biological ageing and healthspan endpoints · Indication assessment
§3.2Obesity and overweight in adults
Anchor outcome. Percentage change in body weight from baseline.
Effect as recorded. No randomised controlled human trial identified; —.[2,3]
Certainty. Very low certainty Rodent diet-induced obesity models only.
Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.
Full evidence extract for obesity and overweight in adults · Indication assessment
§3.3Primary mitochondrial myopathy and bioenergetic disorders
Anchor outcome. Six-minute walk distance.
Effect as recorded. No randomised controlled human trial identified; —.[3,4]
Certainty. Very low certainty —
Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.
Full evidence extract for primary mitochondrial myopathy and bioenergetic disorders · Indication assessment
§3.4Type 2 diabetes mellitus
Anchor outcome. Change in HbA1c (%, mmol/mol).
Effect as recorded. No randomised controlled human trial identified; —.[4]
Certainty. Very low certainty Rodent insulin-sensitivity findings only.
Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.
Full evidence extract for type 2 diabetes mellitus · Indication assessment
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism 2015;21(3):443–454. doi:10.1016/j.cmet.2015.02.009 · PMID 25738459
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6 · PMID 20143256
- Bhattacharyya S, Wang J, Kaplan RM. Quality of peptide products obtained from unregulated online suppliers: an analytical survey. Journal of Pharmaceutical Sciences 2024;113(4):1102–1110. doi:10.1016/j.xphs.2023.11.021 Cited by the Institute as an indicative analytical survey; sample frame was not random.
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.